KORU Medical Systems to Report Third Quarter 2026 Financial Results on November 10, 2026

KORU Medical Systems (KRMD) will report its third quarter 2026 financial results on Tuesday, November 10, 2026.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Conference Call and Webcast Details

The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international callers. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.

About KORU Medical Systems

KORU Medical develops, manufactures, and commercializes innovative and patient-centric subcutaneous infusion solutions that improve quality of life for patients around the world. The Freedom Syringe Infusion System (the “Freedom System”) currently includes the Freedom60^® and FreedomEDGE^® Syringe Infusion Drivers, Precision Flow Rate Tubing^™ and High-Flo Subcutaneous Safety Needle Sets^™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Pharma Services and Clinical Trials business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261020039007/en/

Investor Contact:
Louisa Smith
investor@korumedical.com

Source: KORU Medical Systems, Inc.

Key Terms

subcutaneous infusion medical

Subcutaneous infusion is the slow delivery of a medicine or fluid under the skin through a small needle or thin tube, similar to a drip placed just beneath the surface rather than into a vein. It matters to investors because this way of delivering drugs enables at-home treatment, wearable infusion devices, recurring consumables and lower hospital use, all of which can create steady revenue, affect reimbursement decisions and influence a therapy’s market adoption.

fda clearance regulatory

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.